Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

Science 37 Holdings, Inc.

Jeeva provides AI-powered sales development representative (SDR) solutions for automated lead generation and personalized outreach.

Jeeva

Accelerated Enrollment Solutions (AES) provides services to biopharmaceutical and biotechnology companies for patient recruitment and research site management.

Accelerated Enrollment Solutions (AES)

Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

Novotech

Science 37 is a virtual clinical trial company that focuses on enhancing the quality of clinical research by improving patient access and enrollment, emphasizing diversity in patient populations.

Metric
Company Name	Science 37 Holdings, Inc.	Jeeva	Accelerated Enrollment Solutions (AES)	Novotech
Symbol	SNCE
MSH ID	COM:SCIENCE37	AI:JEEVA	COM:GLOBALAES	COM:NOVOTECH-CRO
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Technology	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Healthcare Information Services	Sales Technology	Clinical Research	Biotechnology Research
Country	US	US	US	AU
Stage		Grant
Employee Count	460			1.99K
Website	science37.com	jeeva.ai	globalaes.com	novotech-cro.com
LinkedIn				novotech
Founders

Metric
Market Cap	34.66M
Enterprise Value
Monthly Web Traffic		16
Web Traffic Growth
Valuation
Raised Capital		1.41M

Metric
Revenue	70.15M
Revenue (LTM)
Revenue (NTM)
Gross Profit	15.87M
EBITDA	-139.41M
Operating Income	-105.33M
Net Income	-50.99M
EPS	-0.44
Diluted EPS	-0.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.30
Operating Profit Margin	-0.49
EBITDA Margin	-1.99
Net Profit Margin	-2.05
Return on Equity	-1.71
Return on Assets	-1.63
Return on Capital Employed	-0.51

COM:SCIENCE37

Science 37

Last Close

5.73

11/03 20:00

Market Cap

34.66M

Beta: -

Volume Today

48.81K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.44
P/B Ratio	12.99
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.58
EV Multiple	6.57

Metric
Days Sales Outstanding	76.26
Days Payables Outstanding	57.46
Days Inventory Outstanding	53.22
Operating Cycle	129.48
Cash Conversion Cycle	72.02
Asset Turnover	0.80

Metric
Operating Cash Flow	-75.44M
Free Cash Flow	-107.32M
Cash Flow to Debt	-82.94
Operating Cash Flow/Sales	-0.80
Free Cash Flow Yield	-2.15

Metric
Cash & Equivalents	108.09M
Accounts Receivable	-821
Inventory
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	4.17
Quick Ratio	3.81

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.29
R&D to Revenue
SG&A to Revenue	0.00